Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ENDO INTERNATIONAL PLC ENDPQ

Healthcare Drug Manufacturers - Specialty & Generic
Endo International plc has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code and is winding down its business. The Company has no business operations.

Recent & Breaking News (GREY:ENDPQ)

Endo Launches PREVDUO(TM) (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

PR Newswire June 12, 2023

Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®

PR Newswire June 5, 2023

Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials

PR Newswire May 24, 2023

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

PR Newswire May 8, 2023

Endo Announces Agreement with Slayback Pharma to Distribute Prevduo(TM) (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.

PR Newswire April 26, 2023

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

PR Newswire April 17, 2023

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

PR Newswire April 3, 2023

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

PR Newswire March 13, 2023

Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules

PR Newswire March 10, 2023

ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS

PR Newswire March 6, 2023

Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease

PR Newswire February 6, 2023

Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)

PR Newswire December 6, 2022

ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS

PR Newswire November 9, 2022

Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool

PR Newswire October 27, 2022

Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting

PR Newswire October 7, 2022

Endo Launches Unscripted Video Series With Real Dupuytren's Contracture Patients

PR Newswire October 5, 2022

Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

PR Newswire August 16, 2022

New Drug Filing for Cenobamate Accepted for Review in Canada and Israel

PR Newswire August 9, 2022

ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

PR Newswire August 9, 2022

Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy

Canada NewsWire August 8, 2022